Enzyme assay kits for lactate dehydrogenase (LDH) and glucose-6-phosphate-dehydrogenase (G6PDH), acid phosphatase (ACP), alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase
(AST) kits were products of Randox Laboratories limited; United Kingdom, and were supplied by LIMED International Limited, Idumota Lagos State, Nigeria.
Thus we aimed at measuring the levels of liver enzymes serum alanine transaminase (ALT) and aspartate transaminase
(AST) in patients of OSAS and to assess the effect of short term CPAP treatment on liver enzymes.
(AST), Alanine transaminase (ALT) and Lactate dehydrogenase (LDH) were measured by IFCC approved kinetic method.
Laboratory test showed slightly elevated alanine aminotransferase (ALT) and aspartate transaminase
(AST; ALT 86 U/L, AST 187 U/L).
In the group given D-GaIN, the following transmission electron microscopic and light microscopic results were found: degenerative changes in the liver tissue, significant decreased in the number of activated Bcl-2, while increased in the number of Bax and caspase-3-positive hepatocytes, a significantly increase in levels of the activities of biochemistry markers (serum alanine transaminase (ALT), aspartate transaminase
(AST) and alkaline phosphatase (ALP)).
Additionally, results of a plasma biochemical panel revealed increased activities of lactate dehydrogenase (LDH) (305 U/L; reference range, 40-250 U/L), aspartate transaminase
(AST) (1483 U/L; reference range, 90-180 U/L), alkaline phosphatase (ALP) (855 U/L; reference range, 290-750 U/L), and creatine kinase (238 U/L; reference range, 280-500) and increased concentration of bile acids (524 [micro]mol/ L; reference range, 6-35 [micro]mol/L).
3]/[micro]L) 379 130-400 Erythrocyte sedimentation 21 0-20 rate (mm/h) C-reactive protein (mg/L) 10 0-5 Anti-nuclear antibody Negative Extractable nuclear antibodies Negative Immunofluorescence assay ANCA Negative Enzyme-linked immunosorbent Negative assay ANCA C3 (mg/dL) 156 90-180 C4 (mg/dL) 19 10-40 Hepatitis B surface antigen Negative Anti-Hepatitis B surface (IU/mL) Negative Anti-Hepatitis C virus Negative Anti-Human immunodeficiency virus Negative Fasting blood glucose (mg/dL) 95 70-110 Alanine transaminase (U/L) 15 <50 Aspartate transaminase
(U/L) 19 <50 Gamma-glutamyl transaminase (U/L) 31 <55 Alkaline phosphatase (U/L) 70 <120 Total bilirubin (mg/dL) 0.
2%; myoglobin by 9% (7% together with CK-MB mass); obsolete markers, such as aspartate transaminase
, lactate dehydrogenase, CK-MB activity, and CK, by 8% of responders, mainly in local laboratories but with a substantial decrease compared to previous 40% in the 2005 survey (3).
6 mg/dL; alanine transaminse (ALT) 161 IU/L; aspartate transaminase
(AST) 104 IU/L; gamma glutamyl transpeptidase (GGT) 24 IU/L; alkaline phosphatase (ALP) 355 IU/L; albumin 3.
Fasting blood tests were taken at baseline and at the end of study and assessed for fasting blood glucose (FBG) serum total cholesterol, TGs, LDLC, high-density lipoprotein cholesterol (HDL-C), and liver enzymes including alanine transaminase (ALT), aspartate transaminase
(AST) and creatinine.
Assessment of liver cell injury is done by the estimation of serum aspartate transaminase
or AST (formerly glutamic oxaloacetic transaminase or SGOT) and serum alanine transaminase or ALT (formerly glutamic pyruvic transaminase or SGPT).
Some studies have demonstrated no change in aspartate transaminase
(AST) and alanine transaminase (ALT), but a rise in bilirubin levels.